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To determine HIV-1 subtypes and antiretroviral drug resistance mutations for 16 infected, pregnant 
women in Jos, Nigeria, part of pol (1040 bp) was amplified from patient PBMC DNA, sequenced and 
analyzed.  Eight of the samples were subtype G, three were CRF02_AG and 2 were unique recombinant 
forms (URF) between G and CRF02_AG. The remaining consisted of 3 different strains: one was subtype 
C, and the other 2 were unrelated URF.  Nearly full-length genome sequences were completed for 6 of 
the strains:  4 subtype G and 2 CRF02_AG.  In the 14 drug-naïve subjects, no primary resistance-asso-
ciated mutations were found, but secondary mutations were identified in 7 different codons of the gene 
coding for protease: PR K20I, M36I, L63A/P/V, V82I, L10M/I and I93L.  In addition, the K238R mutation 
was identified in the reverse transcriptase gene of 3 viruses. The PR K20I and M36I mutations occurred 
in all of the strains, and the L10M and V82I mutations occurred only in subtype G.  The mutation, I93L, 
was carried by subtype C viruses. Two of the women that had prior niverapine treatment, had primary 
resistance-associated mutations, RT M184V and K103N, archived in their proviral DNA several months 
after treatment cessation. The study reports a predominance of clade G and CRF02_AG, and provides 
many more examples of nearly full-length genome sequences for subtype G viruses from Nigeria. The 
ubiquitous presence of PI secondary resistance-associated mutations, as well as primary resistance-
associated mutations in 2 previously treated women, underscores the need to ensure adherence 
compliance to treatment.   
 





Many genetic subtypes of HIV-1 have been characterized 
from diverse geographic regions with a growing number 
of inter-subtype circulating recombinant forms (CRF) 
(http://hiv-web.lanl.gov). There are currently 16 circulating 
recombinant forms (CRFs) in various geographical reg-
ions, including CRF02_AG, an AG recombinant that has 
been reported to account for >50% of the HIV infections 
in Cameroon and other West African populations Carr et 
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rica and Central Asia (Carrion et al., 2003; Carr et al., 
personal communication). Subtype designations are po-
werful epidemiological tools that have been used to track 
the spread of the virus and to determine transmission 
patterns (Jannsens et al., 1997). Data in the literature 
show a heterogeneous distribution of the sub-types and a 
pandemic of geographically localized genetic subtypes 
(Kanki et al., 1997; Peeters et al., 1997). Genetic differ-
ences in the virus impact the efficiency of diagnostic ass-
ays such as viral loads assays (Coste et al., 1996; Triq-
ues et al., 1999) and the susceptibility to antiretroviral 
therapy. Viral genetic differences have been associated 






some subtype G samples have been reported to be less 
susceptible to protease inhibitors (Apetrei et al., 1998; 
Descamps et al., 1997) and subtype O strains are natu-
rally resistant to non nucleoside reverse transcriptase 
inhibitors (Descamps et al., 1995).               
In Nigeria, the first AIDS case was reported in 1986; 
since then seroprevalence jumped from 1.8% in 1991 to 
5% in 2003 (Nigeria sentinel survey, 2003) among ante-
nnatal clinic (ANC) attendees. Several studies have sho-
wn HIV subtype A and G as well as CRF02_AG as the 
predominant strains causing the epidemic in Nigeria. HIV- 
1 from an asymptomatic and AIDS patient from Jos in the 
north central region of Nigeria was first isolated by 
Abimiku et al. (1994) and shown to have a subtype G env 
and gag regions. Full- length genome sequences of these 
isolates showed one of them to be subtype G and one an 
AG recombinant (Gao et al., 1998). In addition, the 
CRF02_AG prototype (IbNG) was described in Ibadan in 
the south-western region by Howard et al. (1994). McCut-
chan et al. (1999) identified subtype G and various forms 
of A/G recombinants in the complete env gene in 10 pati-
ents hospitalized in the Northeastern region of Nigeria. 
Further characterization of the subtype distribution con-
ducted in several states across Nigeria indica- ted the 
selective prevalence of subtype A and the CRF02_AG 
prototype IbNG in southern Nigeria and subtype G in the 
north (Gao et al., 1998; Howard et al. 1994). However 
this regional distribution has not been confirmed by other 
investigators in the field neither have there been studies 
that describe the distribution of subtypes in specific gro-
ups targeted for intervention strategies. With the imple-
mentation of the expanded ARV program and the PMTCT 
in Nigeria, gaps exist with regard to information on the 
actual distribution of HIV-1 subtypes amongst high-risk 
and vulnerable groups in Nigeria such as commercial sex 
workers, pregnant women, young children and youths 
which should be targeted for intervention and control pro-
grams. Our study targets a population of pregnant wom-
en attending the antenatal clinic at the Plateau State Spe-
cialist Hospital (PSSH) and aims to genetically characte-
rize the subtype distribution in an environment in which 
the HIV-1 A/G recombinant was shown to be circulating 
ten years ago( Abimiku et al., 1994). In addition, baseline 
data regarding the viral mutations associated with drug 
resistance obtained from this study are vital in guiding the 
choice of ARV therapy and in controlling the emergence 





Blood was drawn from asymptomatic HIV-1 seropositive antenatal 
clinic attendants, after obtaining consent from them during an 18-
month study (2001 – 2002) to establish baseline epidemiological 
data for HIV infection at the Plateau State Specialist Hospital 
(PSSH) in Jos, Nigeria. Plasma was collected from spun blood and 
peripheral blood mononuclear cells (PBMCs) were separated on 
ficoll gradients, after which the plasma and cells were frozen appro-
priately at –70oC and liquid nitrogen, respectively, until required. 
The frozen samples were later shipped to the Institute of Human Vi- 




rology in Baltimore (IHV) for molecular studies. Genomic DNA was 
isolated from PBMCS utilizing the QIAmp DNA Blood mini Kit (Qia-
gen, Valencia, CA, USA) and the DNA integrity was first determined 
by the amplification of the beta-globulin gene by PCR. 
The region encoding the protease protein and part of the reverse 
transcriptase (RT) protein (Pro/RT)(1.1kb) was amplified using nes-
ted PCR with the following as outer primers: POLF1 (5`-
CWTTRGARGAAATGATGACAGC-3`) and CAMPOLR2 (5`TTCTC-
TGCCAATTCTAATTCTGC-3`), followed by POLF3 (5`RGARCC 
AAGAGCCCCAMCAGC-3`) and CAMPOLR1 (5`CCTGSATAAATC-
TGACTTCC-3`) as inner primers. Cycling conditions for first round 
amplification were the initial denaturation of 95oC for 10 min follo-
wed by 45 cycles of 94oC (30 s) for denaturation, 55oC (30 s) for 
annealing and for extension, 72oC (1.5 min). This was followed by a 
final extension of 72oC for 10 min. Two microlitre of the first round 
reaction served as template for the second round amplification 
reaction and the conditions were an initial denaturation at 95oC for 
10 min, and 30 cycles of 95oC (30 s), 58oC (30s), 72oC (1.5 min), 
and a final extension 72oC for 10 min to inactivate the reaction. In 
some cases several second round reactions were combined in 
order to obtain sufficient template for sequencing. For both reac-
tions the concentration of the components were similar, thus all pri-
mers were diluted at final concentration of 0.1 µM, 1unit of Amplitaq 
gold polymerase was used per reaction, with 200 µM dNTPs, 1.5 
mM MgCl2 and reaction buffer. Positive amplification products were 
purified using Microcon YM-50 columns (AMICON Bioseparation 
kit) and served as template for automated sequencing. PCR Prod-
ucts were directly sequenced using fluorescent dye terminators and 
Applied Biosystems (ABI) model 3100 capillary sequencer.  Both 
sense and antisense strands of the amplified DNA sequences were 
determined. Derived sequences were analyzed and edited with 
Sequencher v 4.1 (Gene codes Inc.) on Macintosh computers, and 
all sequence ambiguities were resolved. 
Multiple alignments of the Pro/RT sequences with selected refer-
ence sequences of subtypes A-K plus CRF01_AE (CM240), CRF02 
_ AG prototype IbNG and NG083 from Nigeria was conducted 
using GDE software, which uses PHYLIP software for the phylo-
genetic analyses (Felsenstein, 1989). A neighbor-joining phyloge-
netic analysis with a maximum parsimony bootstrap was performed 
in order to determine the genetic relationship of the Nigerian strains 
to other reference sequences.  
The region of the Pol gene that was amplified covers coding 
regions for all of the protease protein (99 aa), and part of the rever-
se transcriptase (252 aa). The sequences of the isolates were exa-
mined for protease and RT drug resistance mutations using the 






The study population consisted mostly of married young 
women whose age ranged from 19 to 38 years (average 
25 yrs) (Table 1). The average CD4 count was 539.85 
cells/µl blood (range of 224 - 1183cells/µl blood).  All but 
two women were drug-naive prior to sample collection but 
two women had had niverapine a year before to prevent 
mother to child transmission of HIV-1. The genotypes for 
the regions sequenced are presented (Table 1).  
In phylogenetic analysis of the Pro/RT sequences, the 
majority of the strains (13/16) were grouped into two main 
clusters:  the CRF02_AG group and the subtype G group.  
Situated between these two clusters, were the subtype 
G/CRF02_AG recombinants (Figure 1A). Four isolates 
clustered   closely   with   subtype   G   reference  isolate 
 




Table 1. Demographic features, subtypes and susceptibility of HIV-1 infected women attending the Plateau 


























92NG083 which was first isolated in Jos, Nigeria, in 1992, 
the same location as these strains 9 years later. One 
(1/16) of the strains that clustered with subtype G, 01NG-
PL601, was actually a recombinant between sub-type G 
and CRF02_AG. There was another significant cluster of 
4 subtype G strains (the cluster including 01NGPL674) 
that represented another Nigerian G cluster. Four other 
isolates clustered significantly with reference strains from 
CRF02_AG, although recombinant analysis revealed that 
01NGPL148 was actually recombinant between subtype 
G and CRF02_AG. Two isolates clustered significantly 
with subtype C; one, 01NGPL364, was pure subtype C 
while the other, 01NGPL658, was a recombinant bet-
ween subtype C and an unclassified strain. The sample 
for 01NGPL364 was known to be dually infected because 
cloned envelope sequences derived from the plasma 
contained both clade C and CRF02_AG (data not sho-
wn). Finally, strain 01NGPL490 was an unusual URF 
made up of subtypes A and G, however, the subtype A 
region clustered with CRF01_AE rather than CRF02_AG. 
Full length genome sequence analysis for 6 samples 
(Figure 2) confirmed the classification based on the pol 
region: 4 strains (01NGPL567, 669, 674 and 760) were 
pure subtype G strains and two other isolates (01NGP-
L710 and 01NGPL754) clustered with IbNG and were 
CRF02_AG.  In conclusion, half of the strains were sub-
type G, and CRF02_AG and two were recombinants bet-
ween two genetic forms (G/CRF02AG). The remaining 
isolates were other recombinants and one subtype C. 
The presence of different subtypes and recombinants in 
this small sample is an indication of the diversity of gene-
tic forms circulating among women in Jos. 
Next we examined the Protease/RT sequences for 
mutations that have been shown to be associated with 
increased resistance to PI, NRTI, and NNRTI anti-
retroviral (ARV) drugs in subtype B viruses (Figure 3). All 
but 2 of the women in this study were ARV drug-naïve. 
Among these women, 7 different secondary resistance 
amino acid substitutions were identified in the protease 
and RT regions at codons 10, 20, 36, 63, 82, 93 and 238. 
There were no significant differences in baseline muta-
tions between subtypes G and CRF02_AG, and second-
ary mutations PR K20I and M36I occurred in all of the 
samples of both genetic forms, an observation not seen 
with subtype B. The V82I (62.5%) and L10M (25%) muta-
tions occurred only in subtype G isolates and I93L occur-
red only in the pure subtype C and the C recombinant 
samples. Other mutations that were identified include 
L63A/P/V and K238R. Further observation of the frequen-
cy of the mutations carried by each isolate shows that 
most of them harbored more than 2 mutations, and some 
isolates had accumulated up to 4 different mutations. 
More than 50% of the sequences showed low level 
potential to develop resistance to PIs. No major muta-
tions associated with drug resistance were detected for 
protease inhibitors. Two of the women had had nivera-
pine (NVP) treatment during an earlier birth to interrupt 
mother-to-child transmission. Examination for primary 
resistance-associated mutations in the reverse transcript-
tase gene of those women revealed the presence of 
M184V and K103N in one sample (01NGPL338) and 
K103N only in another (01NGPL674). Both of these stra-
ins were subtype G. These isolates each carried 3 or 4 
different secondary polymorphisms respectively and were 
Drug resistance Sample ID Age CD4 Count ARV 
experience PI, NRTI, NNRTI 
PRO/RT 
Subtype 
01NGPL148 29 237 Naïve Susceptible G/CRF02_AG 
01NGPL209 20 511 Naïve Susceptible G 
01NGPL338 31 - NVP Resistant G 
01NGPL364 28 482 Naïve Susceptible C 
01NGPL368 26 423 Naïve Susceptible G 
01NGPL490 26 569 Naïve Susceptible A/G/CRF01_AE 
01NGPL567 19 1183 Naïve Susceptible CRF02_AG 
01NGPL601 21 ND Naïve Susceptible G 
01NGPL644 35 301 Naïve Susceptible CRF02_AG 
01NGPL658 21 256 Naïve Susceptible C/unclassified 
01NGPL674 38 1127 NVP resistant G 
01NGPL669 30 224 Naïve Susceptible G 
01NGPL710 26 573 Naïve Susceptible CRF02_AG 
01NGPL754 24 453 Naïve Susceptible G 
01NGPL760 21 506 Naïve Susceptible G/CRF02_AG 



































































Figure 1.  Phylogenetic analysis of Nigerian Pro/RT sequences from 
HIV-1 positive pregnant women from Jos, Nigeria. Neighbor-joining 
analysis was performed using the Kimura 2-parameter (gamma) 
method of distance estimation; bootstrap values were computed 
using Neighbor-joining and values > 70% is indicated with dots at 
the respective nodes. A) Radial phylogenetic tree of 16 Nigerian 
protease/RT sequences with reference sequences of different sub-
types. Nigerian sequences (in Bold), reference sequences (small 
type). B) Distribution of HIV-1 subtypes among infected pregnant 
women in Jos, Nigeria. The pie chart demonstrates the proportion of 







Figure 2. Circular phylogenetic tree of 6 nearly full genome 
sequences with reference sequences of different subtypes. 
Nigerian sequences (boxed), reference sequences (not 
boxed). Full-length genomes confirm PRO/RT classification. 









Our analysis provides evidence for the presence of sub-
type G and CRF02_AG isolates in Jos, nine years earlier 
the first isolate from Jos, Nigeria was characterized as a 
subtype G (Gao et al., 1998; Howard et al., 1994). This 
strain was distinct from the CRF02_AG proto-type IbNG 
isolate from Ibadan, Nigeria, which was mostly subtype 
A. Other studies have documented the presence of sub-
types A and G, CRF02_AG and various forms of AG 
recombinants as well as a low level prevalence of sub-
type C (Peters et al., 2000; Agwale et al., 2002) in differ-
ent geographic regions of Nigeria. The presence of mixed 
circulating recombinants in Nigeria is confirmed and ext-
ended by the contribution of 6 nearly full length genomes 
from Jos, Nigeria in this study (Figure 2).  
This study demonstrates for the first time in this popu-
lation the high prevalence of secondary resistance asso-
ciated mutations in Protease present before the initiation 
of therapy. There were secondary mutation sites at cod-
ons 10, 20, 36, 63 and 82 for most of the strains and 
mutation I93L for the subtype C strains. The prevalence 
of these mutations in this population differs from those 
described for subtype B viruses in the same codons. 
Thus while the frequency of mutations at codons 10, 20, 
and 36 was 2-7% among drug naïve individuals with sub-
type B infection, it was higher (21.74, 100 and 105%) in 
this study and in other studies (Hirsch et al., 2000; Kon-
ings et al., 2004; Fonjungo et al., 2002) of non-B viruses. 
These data provide baseline information on the level of 
drug resistance in this environment, where access to anti-
retroviral therapy is being scaled up. Vergne et al. (2000) 
did not find any primary mutations associated with NRTI 
or PI in non-B HIV-1 isolates from 142 ARV- naïve pati-
ents, but reported the presence of many secondary muta-
tions, especially at codons 36, 10,63,20,77 and 71. The 
mutation at position 63 is poly-morphic and most of the 
isolates harbored the L63P mutation, and three viruses 
(two CRF02-AG and one subtype C) showed the K238R 
polymorphism that might be linked to the novel mutation 
(K238S) associated with niverapine resistance (Hachiya 
et al., 2004). Gonzales et al. (2001) had shown that viral 
differences occur among amino acid substitutions related 
to drug resistance in subtype B and non-B isolates. They 
also revealed that secondary mutations in positions 10, 
20 and 36 of the protease gene are more common in 
non-B viruses. Several other studies in non- subtype B 
viruses show that secondary mutations are common bef-
ore treatment, suggesting there could be background 
effect on the susceptibility to ARVs. Our study is consis-
tent with these reports on the high prevalence of second-
ary mutations that are associated with susceptibility to 
antiretroviral treatment in the Pol region in treatment naï-
ve isolates of non B subtypes, and could impact signi-
ficantly on susceptibility to PIs. The relevance of our  find- 
 




ings will need to be evaluated in these women or other 
persons undergoing therapy in order to understand their 
relationship to the evolution of primary resistance muta-
tions in specific geographic clades. Already, it has been 
suggested that the presence of secondary mutation M36I 
at baseline has the potential for predicting the appea-
rance of the primary mutation L90M, which is associated 
with resistance to all protease inhibitors, at virological 
failure in an Italian cohort with a high proportion of non 
subtype B isolates of HIV (Perno et al., 2004). 
The primary mutations observed at RT codons 184 
and 103 associated with 3TC and NVP resistance in the 
two drug-experienced women are of concern especially in 
the treated population where niverapine prophylaxis is 
already in use. It is an indication of a high probability of 
the evolution of widespread resistance to protease and 
reverse transcriptase inhibitors in this population where 
subtype G and its recombinants are prevalent. A prelimi-
nary study had shown that the niverapine resistance 
mutations (K103N) were readily selected in Ugandan 
women who received a single dose prophylactic regimen 
at the onset of labor in the Phase I/II trial HIVNET 006 





Our results support previous studies that subtypes G and 
AG recombinants are predominant in Nigeria, but the pre-
sence of new recombinant forms and other subtypes not 
known to commonly circulate may further complicate the 
epidemiology of HIV in this region. While the absence of 
primary resistance mutations among the treatment naïve 
isolates portends well for the use of PIs and other nucle-
otide and non-nucleoside reverse transcriptase inhibitors, 
care must be taken in the management of adherence and 
treatment administration in order to prevent the develop-
ment and transmission of resistance given the high back-
ground of secondary mutations among HIV-1 isolates 
observed in this study. Our study clearly underscores the 
need for continuous monitoring of the HIV epidemic in 
Nigeria especially with the significant increase in HIV 
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The sequences of the pro/RT are found in Genbank ac-
cession numbers DQ013268-DQ013283. Disclaimer:  
The views and opinions expressed herein do not neces-








Abimiku AG, Stern TL, Zwandor A, Markham PD, Calef C, Kyari S, 
Saxinger WC, Gallo RC, Robert-Guroff M, Reitz MS (1994). 
Subgroup G HIV type 1 isolates from Nigeria. AIDS Res Hum 
Retroviruses. Nov; 10(11): 1581-1583. 
Agwale SM, Zeh C, Robbins KE, Odama L, Saekhou A, Edubio A, 
Njoku M, Sani-Gwarzo N, Gboun MS, Gao F, Reitz M, Hone D, 
Pieniazek D, Wambebe C, Kalish ML (2002). Molecular surveillance 
of HIV-1 field strains in Nigeria in preparation for vaccine trials. 
Vaccine. May 15; 20(16): 2131-2139. 
Apetrei C, Descamps D, Collin G, Loussert-Ajaka I, Damond F, Duca M, 
Simon F, Brun-Vezinet F (1998).Human immunodeficiency virus 
type 1 subtype F reverse transcriptase sequence and drug 
susceptibility. J Virol. 72: 3534-3538. 
Carr JK, Nadai Y, Eyzaguirre L, Saad MD, Khakimov MM, Yakubov SK, 
Birx DL, Graham RR, Earhart KC (2003). Sanchez JL.  Outbreak of 
West African Recombinant of HIV-1 in Tashkent, Uzbekistan.  J 
AIDS in press. 
Carr JK, Torimiro JN, Wolfe ND, Eitel MN, Kim B, Sanders-Buell E, 
Jagodzinski LL, Gotte D, Burke DS, Birx DL, McCutchan FE (2001) 
.The AG recombinant IBNG and novel strains of group M HIV-1 are 
common in Cameroon. Virology. Jul 20; 286(1): 168-181. 
Carrion G, Hierholzer J, Montano S, Alava A, Perez J, Guevara A, 
Laguna-Torres V, Mosquera C, Russell K, Chauca G, Kochel T, Birx 
DL, Sanchez JL, Carr JK (2003). Circulating recombinant form,   
CRF02_AG in South America. AIDS Res Hum Retroviruses. Apr.; 
19(4):329-32. 
Coste J, Montes B, Reynes J, Peeters M, Segarra C, Vendrell JP, 
Delaporte E, Segondy M (1996). Comparative evaluation of three 
assays for the quantitation of human immunodeficiency virus type 1 
RNA in plasma. J Med Virol. Dec;50(4):293-302. 
Descamps D, Apetrei C, Collin G, Damond F, Simon F, Brun-Vezinet F 
(1997). Naturally occurring decreased susceptibility of HIV-1 subtype 
G to protease inhibitors. AIDS, 1998; 12: 1109-1111. 
Descamps D, Collin G, Loussert-Ajaka I, Saragosti S, Simon F, Brun-
Vezinet F (1995): HIV-1 group O sensitivity to antiretroviral drugs 
[letter]. AIDS, 9: 977-978. 
Felsenstein, J. (1989). PHYLIP-phylogenetic inference package 
(version 3.2). Clad. 5, 164-166. 
Fonjungo PN, Mpoudi EN, Torimiro JN, Alemnji GA, Eno LT, 
Nkengasong JN, Gao F, Rayfield M, Folks TM, Pieniazek D, Lal RB 
(2002). Presence of diverse human immunodeficiency virus type 1 
viral variants in Cameroon. AIDS Res Hum Retroviruses 16: 1319–
1324. 
Gao F, Robertson DL, Carruthers CD, Morrison SG, Jian B, Chen Y, 
Barre-Sinoussi F, Girard M, Srinivasan A, Abimiku AG, Shaw GM, 
Sharp PM, Hahn BH (1998). A comprehensive panel of near-full-
length clones and reference sequences for non-subtype B isolates of 
human immunodeficiency virus type 1. J. Virol. 72(7): 5680-5698. 
Gonzales MJ, Machekano RN, Shafer RW (2001) Human 
immunodeficiency virus type 1 reverse-transcriptase and protease 
subtypes: classification, amino acid mutation patterns, and 
prevalence in a northern California clinic-based population. Infect 
Dis. 184(8): 998-1006.  
Hachiya A, Gatanaga H, Kodama E, Ikeuchi M, Matsuoka M, Harada S, 
Mitsuya H, Kimura S, Oka S (2004) Novel patterns of niverapine 
resistance-associated mutations of human immunodeficiency virus 
type 1 in treatment-naive patients.Virology. 327(2): 215-224. 
Hirsch MS, Brun-Vezinet F, D'Aquila RT, Hammer SM, Johnson VA, 
Kuritzkes DR, Loveday C, Mellors JW, Clotet B, Conway B, Demeter 
LM, Vella S, Jacobsen DM, Richman DD (2000). Antiretroviral Drug 
Resistance Testing in adult HIV-1 infection. JAMA may 10; 283(18): 
2417-2426. 
Howard TM, Olaylele DO, Rasheed S (1994). Sequence analysis of the 
glycoprotein 120 coding region of a new HIV type 1 subtype A strain 
(HIV-1 IBNg) from Nigeria. AIDS Res Hum Retroviruses. Dec; 
10(12):1755-7. 
Jackson JB, Becker-Pergola G, Guay LA, Musoke P, Mracna M, Fowler 
MG, Mofenson LM, Mirochnick M, Mmiro F, Eshleman SH (2000) 
Identification of The K103N résistance mutation in Ugandan women  







Jannsens Wouter, Buve Anne, Nkengasong, John N. (1997) .The 
puzzle of HIV-1 subtypes in Africa. AIDS. 11(6):705-712, May 11.  
Kanki PJ, Peeters M, Gueye-Ndiaye A (1997). Virology of HIV-1 and 
HIV-2: implications for Africa. AIDS; 11 Suppl B: S33-42. 
Konings FA, Zhong P, Agwara M, Agyingi L, Zekeng L, Achkar JM, 
Ewane L, Saa, Afane Ze E, Kinge T, Nyambi PN (2004).Protease 
mutations in HIV-1 non-B strains infecting drug-naive villagers in 
Cameroon. J Infect Dis. 2001 Oct 15; 184(8): 998-1006. Epub 2001. 
McCutchan FE, Carr JK, Bajani M, Sanders-Buell E, Harry TO, Stoeckli 
TC, Robbins KE, Gashau W, Nasidi A, Janssens W, Kalish ML 
(1999). Subtype G and multiple forms of A/G intersubtype 
recombinant human immunodeficiency virus type 1 in Nigeria. 
Virology. Feb 15; 254(2): 226-234. 
Nigeria sentinel survey 2003. 
Peeters M, Gueye-Ndiaye A. (1997). Virology of HIV-1 and HIV-2: 
implications for Africa. AIDS; 11 Suppl. B: S33-42. 
Perno CF, Cozzi-Lepri A, Forbici F, Bertoli A, Violin M, Stella Mura M, 
Cadeo G, Orani A, Chirianni A, De Stefano C, Balotta C, d'Arminio 
Monforte A; Italian Cohort Naive Antiretrovirals Study Group. (2004). 
Minor mutations in HIV protease at baseline and appearance of 
primary mutation L90M in patients for whom their first protease-






















































Peeters M, Esu-Williams E, Vergne L, Montavon C, Mulanga-Kabeya C, 
Harry T, Ibironke A, Lesage D, Patrel D, Delaporte E (2000). 
Predominance of subtypes A and G HIV type 1 in Nigeria, with 
geographical differences in their distribution. AIDS Res Hum 
Retroviruses. Mar 1; 16(4): 315-325. 
Triques K, Coste J, Perret JL, Segarra C, Mpoudi E, Reynes J, 
Delaporte E, Butcher A, Dreyer K, Herman S, Spadoro J, Peeters M 
(1999) .Efficiencies of four versions of the AMPLICOR HIV-1 
MONITOR test for quantification of different subtypes of human 
immunodeficiency virus type 1. J Clin Microbio. Jan; 37(1):110-116. 
Vergne L, Peeters M, Mpoudi-Ngole E, Bourgeois A, Liegeois F, Toure-
Kane C, Mboup S, Mulanga-Kabeya C, Saman E, Jourdan J, 
Reynes J, Delaporte E (2000). Genetic diversity of protease and 
reverse transcriptase sequences in non-subtype-B human 
immunodeficiency virus type 1 strains: evidence of many minor drug 
resistance mutations in treatment-naive patients. J Clin Microbiol. 
38: 3919-3925. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
